LIVN

LivaNova's operating business is quietly improving: FY2025 revenue grew 10.7% to $1.39B (its best growth in the five-year history shown), gross margin held at a healthy 67.7%, and operating income jumped 54.5% to $199M for a 14.4% operating margin. Operating cash flow rose 39% to $254M and cash on the balance sheet swelled to $636M (+48%), while long-term debt was cut 37% to $345M. Underneath the GAAP wreckage, this looks like a cash-generative medtech franchise with improving operating leverage on its electromedical/neuromodulation portfolio.

The headline is the FY2025 net loss of -$242M (vs. +$63M in FY2024, a -483.5% swing) and -$4.45 diluted EPS, which drove ROE to -20.2% and pushed retained earnings deeper into deficit at -$1.15B. With operating income clearly positive and growing, the loss is almost certainly driven by below-the-line items (likely the long-running 3T Heater-Cooler product-liability matters and/or impairment/litigation charges that have historically punctuated LivaNova's results) rather than core operations — but the 10-K excerpt provided is boilerplate Items 9-15 with no Risk Factors or MD&A narrative explaining the swing, so the precise cause is not disclosed in the data given. That opacity, combined with current liabilities doubling YoY to $808M (+106.1%), is a real flag: it suggests a sizable accrual or near-term obligation was reclassified into current.